Abstract

Zika virus (ZIKV), a flavivirus with homology to dengue virus (DENV), is spreading to areas of DENV hyper-endemicity. Heterologous T cell immunity, whereby virus-specific memory T cells are activated by variant peptides derived from a different virus, can lead to enhanced viral clearance or diminished protective immunity and altered immunopathology. In mice, CD8+ T cells specific for DENV provide in vivo protective efficacy against subsequent ZIKV infection. In humans, contrasting studies report complete absence or varying degrees of DENV/ZIKV T cell cross-reactivity. Moreover, the impact of cross-reactive T cell recognition on the anti-viral capacity of T cells remains unclear. Here, we show that DENV-specific memory T cells display robust cross-reactive recognition of ZIKV NS3 ex vivo and after in vitro expansion in respectively n = 7/10 and n = 9/9 dengue-immune individuals tested. In contrast, cross-reactivity toward ZIKV capsid is low or absent. Cross-reactive recognition of DENV or ZIKV NS3 peptides elicits similar production of the anti-viral effector mediators IFN-γ, TNF-α, and CD107a. We identify 9 DENV/ZIKV cross-reactive epitopes, 7 of which are CD4+ and 2 are CD8+ T cell epitopes. We also show that cross-reactive CD4+ and CD8+ T cells targeting novel NS3 epitopes display anti-viral effector potential toward ZIKV-infected cells, with CD8+ T cells mediating direct lyses of these cells. Our results demonstrate that DENV NS3-specific memory T cells display anti-viral effector capacity toward ZIKV, suggesting a potential beneficial effect in humans of pre-existing T cell immunity to DENV upon ZIKV infection.

Highlights

  • We first investigated the extent of cross-reactive T cell recognition of Zika virus (ZIKV) antigens by dengue-specific memory T cells and asked whether cross-reactivity could be detected in both CD4+ and CD8+ T cell compartments

  • Due to cell number limitations of our samples we focused our study on the structural protein capsid and the nonstructural protein NS3, which represent the main targets of the CD4+ and CD8+ (NS3) T cell response to dengue virus (DENV) [33,34,35]

  • Cross-reactive recognition of ZIKV capsid was detected only for the CD4+ T cell subset albeit at significantly lower levels compared to its DENV counterpart (Figure 1C)

Read more

Summary

Introduction

Our results demonstrate that DENV NS3-specific memory T cells display anti-viral effector capacity toward ZIKV, suggesting a potential beneficial effect in humans of pre-existing T cell immunity to DENV upon ZIKV infection. Recent studies have shown that human DENV E protein-reactive antibodies crossreact with ZIKV but are poorly neutralizing and instead potently enhance ZIKV infection in vitro, through a mechanism termed antibody dependent enhancement [10, 11] One of these studies addresses whether cross-reactive T cells could play a similar detrimental role upon ZIKV infection, no evidence of cross-reactive CD4+ T cell recognition between DENV and ZIKV envelope and NS1 proteins is found [10]. These data support findings from the mouse studies and point toward a potential beneficial role of dengue-specific crossreactive T cells during ZIKV infection

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.